Adbry/Adtralza Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to limitations of topical corticosteroids, rising prevalence of atopic dermatitis, success of monoclonal antibody treatments, dermatologist acceptance of biologics, regulatory approvals for il targeted therapies.

The growth in the forecast period can be attributed to growing eczema patient population, expansion into pediatric use, increasing biologic therapy awareness, improved reimbursement coverage, continued innovation in dermatology biologics. Major trends in the forecast period include rising adoption of targeted dermatology biologics, growing use in moderate to severe atopic dermatitis, expansion of il 13 targeted therapies, increasing long term maintenance biologic therapy, higher patient demand for steroid sparing treatments.

The increasing prevalence of atopic dermatitis is expected to drive the growth of the Adbry/Adtralza market in the coming years. Atopic dermatitis, commonly referred to as eczema, is a chronic inflammatory skin disorder marked by persistent itching, redness, and skin irritation. The rising occurrence of atopic dermatitis is linked to factors such as higher levels of air pollution, urban lifestyles, changes in childhood skincare routines, and genetic susceptibility. Adbry/Adtralza, a monoclonal antibody that targets the interleukin-13 (IL-13) pathway, helps manage atopic dermatitis by reducing inflammation and excessive immune responses, thereby easing symptoms including itching, redness, and skin irritation in patients with moderate-to-severe disease. For example, in December 2023, according to the National Library of Medicine (NLM), a US-based biomedical library, the global prevalence of atopic dermatitis was estimated at 2.6%, affecting approximately 204.05 million people worldwide, including about 101.27 million adults and 102.78 million children. As a result, the growing prevalence of atopic dermatitis is fueling the growth of the Adbry/Adtralza market.

Rising healthcare expenditure is also expected to support the expansion of the Adbry/Adtralza market. Healthcare expenditure refers to the total spending on health services and related activities over a given period, typically measured annually. Increased healthcare spending plays a vital role in improving the availability and accessibility of innovative therapies such as Adbry (also known as Adtralza), as greater investment in healthcare systems enables broader coverage and distribution of advanced biologic treatments for conditions like moderate-to-severe atopic dermatitis. This, in turn, helps improve patient outcomes while expanding access to essential therapies. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government agency, total healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, compared with a growth rate of 0.9% in 2022. In addition, total long-term health and social care expenditure rose by 2.8% in real terms in 2022. Therefore, increasing healthcare expenditure is contributing to the growth of the Adbry/Adtralza market.

Major companies operating in the Adbry/Adtralza market are concentrating on the development and approval of biologic therapies specifically designed to inhibit interleukin-13 (IL-13) in order to achieve improved treatment outcomes for patients with atopic dermatitis. Biologic therapies are treatments derived from biological sources, such as monoclonal antibodies or proteins, that precisely target components of the immune system or disease-related cellular pathways, offering more targeted and effective management of chronic inflammatory conditions. For example, in December 2023, Leo Pharma, a Denmark-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) expanded the approval of Adbry (tralokinumab-ldrm) to include pediatric patients aged 12 to 17 years with moderate-to-severe atopic dermatitis. This expansion established Adbry as the first and only biologic specifically designed to inhibit IL-13, a key cytokine involved in the inflammatory processes underlying atopic dermatitis.

Major companies operating in the adbry/adtralza market are LEO Pharma Inc.

North America was the largest region in the adbry/adtralza market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adbry/adtralza market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the adbry/adtralza market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have moderately impacted the adbry adtralza market by increasing costs for imported monoclonal antibody inputs and injectable drug components. These impacts are most pronounced across specialty pharmacy and hospital channels in europe and north america. Higher tariffs have added pressure on biologic pricing structures. At the same time, they are encouraging regional biologic manufacturing investments. This supports stronger supply chains and long term treatment accessibility.

The adbry/adtralza market research report is one of a series of new reports that provides adbry/adtralza market statistics, including adbry/adtralza industry global market size, regional shares, competitors with a adbry/adtralza market share, detailed adbry/adtralza market segments, market trends and opportunities, and any further data you may need to thrive in the adbry/adtralza industry. This adbry/adtralza market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Adbry, also known as Adtralza, is a monoclonal antibody therapy used to treat moderate to severe eczema, also called atopic dermatitis, in adults and children aged six years and older. It works by blocking interleukin-13 (IL-13), a protein that plays a key role in the inflammatory process associated with eczema. By targeting IL-13, Adbry/Adtralza helps alleviate skin inflammation, itching, and rashes.

The primary indications for Adbry/Adtralza include atopic dermatitis and other dermatological conditions. Atopic dermatitis is a long-term skin disorder marked by itchy and inflamed skin, which can cause considerable discomfort and interfere with daily activities. These treatments are distributed through channels such as hospitals and clinics, as well as retail and specialty pharmacies, and are used by end users including adult and geriatric patients.

The adbry/adtralza market consists of sales of adbry (Tralokinumab-ldrm), adtralza (Tralokinumab), delgocitinib, TMB-001, and fucidin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.